Healthcare provider profile · identity verified

Joseph Jackson, DO

Family Practice · OKOLONA, MS · NPI 1922074806

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	445	126
Losartan Potassium	Losartan Potassium	363	99
Metoprolol Succinate	Metoprolol Succinate	292	83
Atorvastatin Calcium	Atorvastatin Calcium	286	81
Furosemide	Furosemide	232	69
Albuterol Sulfate Hfa	Albuterol Sulfate	231	77
Metformin Hcl Er	Metformin Hcl	222	62
Gabapentin	Gabapentin	201	54
Famotidine	Famotidine	196	68
Lisinopril	Lisinopril	184	49
Carvedilol	Carvedilol	183	53
Pravastatin Sodium	Pravastatin Sodium	179	44
Montelukast Sodium	Montelukast Sodium	160	49
Rosuvastatin Calcium	Rosuvastatin Calcium	148	43
Omeprazole	Omeprazole	143	42
Spironolactone	Spironolactone	117	31
Tamsulosin Hcl	Tamsulosin Hcl	109	34
Prednisone	Prednisone	106	52
Diclofenac Sodium	Diclofenac Sodium	95	36
Potassium Chloride	Potassium Chloride	93	32
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	93	32
Levothyroxine Sodium	Levothyroxine Sodium	88	23
Pioglitazone Hcl	Pioglitazone Hcl	85	24
Fluticasone Propionate	Fluticasone Propionate	81	28
Chlorthalidone	Chlorthalidone	79	24
Amoxicillin	Amoxicillin	77	66
Allopurinol	Allopurinol	76	19
Simvastatin	Simvastatin	73	19
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	72	20
Tizanidine Hcl	Tizanidine Hcl	71	31
Farxiga	Dapagliflozin Propanediol	67	14
Triamcinolone Acetonide	Triamcinolone Acetonide	67	38
Azithromycin	Azithromycin	66	53
Pantoprazole Sodium	Pantoprazole Sodium	63	23
Eliquis	Apixaban	62	16
Isosorbide Mononitrate Er	Isosorbide Mononitrate	60	13
Colchicine	Colchicine	58	17
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	57	15
Valsartan	Valsartan	54	14
Nabumetone	Nabumetone	53	38
Cefuroxime	Cefuroxime Axetil	51	36
Fluconazole	Fluconazole	49	30
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	49	suppressed
Meloxicam	Meloxicam	49	16
Metformin Hcl	Metformin Hcl	48	14
Hydrochlorothiazide	Hydrochlorothiazide	44	16
Jardiance	Empagliflozin	44	14
Mirtazapine	Mirtazapine	44	15
Clopidogrel	Clopidogrel Bisulfate	43	14
Escitalopram Oxalate	Escitalopram Oxalate	39	suppressed
Ozempic	Semaglutide	39	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	38	31
Symbicort	Budesonide/Formoterol Fumarate	38	11
Duloxetine Hcl	Duloxetine Hcl	37	suppressed
Levetiracetam	Levetiracetam	36	suppressed
Methylprednisolone	Methylprednisolone	36	34
Trimethoprim	Trimethoprim	36	26
Donepezil Hcl	Donepezil Hcl	35	11
Buspirone Hcl	Buspirone Hcl	34	suppressed
Nitroglycerin	Nitroglycerin	33	15
Amitriptyline Hcl	Amitriptyline Hcl	32	12
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	32	suppressed
Mupirocin	Mupirocin	32	16
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	31	suppressed
Lovastatin	Lovastatin	31	suppressed
Doxepin Hcl	Doxepin Hcl	30	suppressed
Atenolol	Atenolol	27	suppressed
Tradjenta	Linagliptin	27	suppressed
Cefdinir	Cefdinir	26	25
Ondansetron Hcl	Ondansetron Hcl	26	16
Ventolin Hfa	Albuterol Sulfate	26	12
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	25	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	24	suppressed
Linzess	Linaclotide	23	suppressed
Trulicity	Dulaglutide	23	suppressed
Hydralazine Hcl	Hydralazine Hcl	22	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	22	suppressed
Lamotrigine	Lamotrigine	21	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	21	suppressed
Promethazine Hcl	Promethazine Hcl	21	suppressed
Sertraline Hcl	Sertraline Hcl	21	suppressed
Ezetimibe	Ezetimibe	20	suppressed
Lactulose	Lactulose	20	suppressed
Sucralfate	Sucralfate	20	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Levofloxacin	Levofloxacin	19	15
Meclizine Hcl	Meclizine Hcl	19	13
Nystatin	Nystatin	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	17	13
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	17	14
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	17	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	16	suppressed
Myrbetriq	Mirabegron	16	suppressed
Baclofen	Baclofen	15	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Januvia	Sitagliptin Phosphate	15	suppressed
Cephalexin	Cephalexin	14	suppressed
Clonidine Hcl	Clonidine Hcl	14	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	14	suppressed
Propafenone Hcl	Propafenone Hcl	14	suppressed
Verapamil Er	Verapamil Hcl	14	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	13	suppressed
Cilostazol	Cilostazol	13	suppressed
Fluocinonide	Fluocinonide	13	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	13	suppressed
Irbesartan	Irbesartan	13	suppressed
Jentadueto	Linagliptin/Metformin Hcl	13	suppressed
Nateglinide	Nateglinide	13	suppressed
Novolin N	Insulin Nph Human Isophane	13	suppressed
Finasteride	Finasteride	12	suppressed
Mometasone Furoate	Mometasone Furoate	12	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Citalopram Hbr	Citalopram Hydrobromide	11	suppressed
Entresto	Sacubitril/Valsartan	11	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Warfarin Sodium	Warfarin Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error